Skip to content

Depreciation at other companies

Danaher logo
DanaherDHR
Illumina logo
IlluminaILMN
AbCellera Biologics Inc. logo
AbCellera Biologics Inc.ABCL
Apogee Therapeutics, Inc. logo
Apogee Therapeutics, Inc.APGE

Other financials

Income statement

See full
Revenue$65.8M+40.5%
Gross profit$33.7M+336%
Operating income-$2.2M+95.6%
Net income-$3.7M+87.5%
EPS (diluted)-$0.02+90.5%

Balance sheet

See full
Cash & equivalents$165.9M-41.8%
Total debt$270.9M-17.1%
Total equity$211.6M-29.6%
Total assets$713.2M-25.7%

Cash flow

See full
Operating cash flow$8.7M+192%
CapEx$4.4M-1.4%
Free cash flow$4.2M+130%

Valuation

See full
Market cap$902.74M+204%
Enterprise value$1.01B+198%
P/S4.4×+3.2×

Profitability

See full
Gross margin29.3%-8.0pp
Operating margin-82.2%-16.6pp
Net margin-51.1%-9.9pp
FCF margin-25.7%

Returns & leverage

See full
Return on equity-40.8%-4.0pp
Debt / equity1.3×+0.2×
Current ratio5.9×-0.1×

Where this comes from

Reported directly by Maravai LifeSciences Holdings, Inc. in its filing.

Tagged under the XBRL concept us-gaap:Depreciation.

The official record: Maravai LifeSciences Holdings, Inc.’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Maravai LifeSciences Holdings, Inc.'s depreciation.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Maravai LifeSciences Holdings, Inc.'s depreciation?
Maravai LifeSciences Holdings, Inc. (MRVI) reported depreciation of $4.9M in Q1 2026.
How has Maravai LifeSciences Holdings, Inc.'s depreciation changed year-over-year?
Maravai LifeSciences Holdings, Inc.'s depreciation decreased by 13.9% year-over-year, from $5.69M to $4.9M.
What is the long-term trend for Maravai LifeSciences Holdings, Inc.'s depreciation?
Over 4 years (2021 to 2025), Maravai LifeSciences Holdings, Inc.'s depreciation has grown at a 38.4% compound annual growth rate (CAGR), from $6.41M to $23.56M.